Literature DB >> 22183892

The receptor that tames the innate immune response.

Michael Brines1, Anthony Cerami.   

Abstract

Tissue injury, hypoxia and significant metabolic stress activate innate immune responses driven by tumor necrosis factor (TNF)-α and other proinflammatory cytokines that typically increase damage surrounding a lesion. In a compensatory protective response, erythropoietin (EPO) is synthesized in surrounding tissues, which subsequently triggers antiinflammatory and antiapoptotic processes that delimit injury and promote repair. What we refer to as the sequelae of injury or disease are often the consequences of this intentionally discoordinated, primitive system that uses a "scorched earth" strategy to rid the invader at the expense of a serious lesion. The EPO-mediated tissue-protective system depends on receptor expression that is upregulated by inflammation and hypoxia in a distinctive temporal and spatial pattern. The tissue-protective receptor (TPR) is generally not expressed by normal tissues but becomes functional immediately after injury. In contrast to robust and early receptor expression within the immediate injury site, EPO production is delayed, transient and relatively weak. The functional EPO receptor that attenuates tissue injury is distinct from the hematopoietic receptor responsible for erythropoiesis. On the basis of current evidence, the TPR is composed of the β common receptor subunit (CD131) in combination with the same EPO receptor subunit that is involved in erythropoiesis. Additional receptors, including that for the vascular endothelial growth factor, also appear to be a component of the TPR in some tissues, for example, the endothelium. The discoordination of the EPO response system and its relative weakness provide a window of opportunity to intervene with the exogenous ligand. Recently, molecules were designed that preferentially activate only the TPR and thus avoid the potential adverse consequences of activating the hematopoietic receptor. On administration, these agents successfully substitute for a relative deficiency of EPO production in damaged tissues in multiple animal models of disease and may pave the way to effective treatment of a wide variety of insults that cause tissue injury, leading to profoundly expanded lesions and attendant, irreversible sequelae.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22183892      PMCID: PMC3356428          DOI: 10.2119/molmed.2011.00414

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  86 in total

1.  Erythropoietin administration induces an increase of serum levels of soluble E-selectin and soluble intercellular adhesion molecule 1.

Authors:  A Allegra; M Buemi; F Corica; C Aloisi; N Frisina
Journal:  Nephron       Date:  1999       Impact factor: 2.847

2.  Dimerization of the erythropoietin receptor transmembrane domain in micelles.

Authors:  Alexandra Z Ebie; Karen G Fleming
Journal:  J Mol Biol       Date:  2006-11-11       Impact factor: 5.469

3.  Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties.

Authors:  Chanil Moon; Melissa Krawczyk; Doojin Paik; Thomas Coleman; Michael Brines; Magdalena Juhaszova; Steven J Sollott; Edward G Lakatta; Mark I Talan
Journal:  J Pharmacol Exp Ther       Date:  2005-11-23       Impact factor: 4.030

4.  A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells.

Authors:  Moonkyoung Um; Alec W Gross; Harvey F Lodish
Journal:  Cell Signal       Date:  2006-08-30       Impact factor: 4.315

Review 5.  IL-3, IL-5, and GM-CSF signaling: crystal structure of the human beta-common receptor.

Authors:  James M Murphy; Ian G Young
Journal:  Vitam Horm       Date:  2006       Impact factor: 3.421

6.  An endogenous peptide signal in Arabidopsis activates components of the innate immune response.

Authors:  Alisa Huffaker; Gregory Pearce; Clarence A Ryan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-19       Impact factor: 11.205

7.  A potential role for erythropoietin in focal permanent cerebral ischemia in mice.

Authors:  M Bernaudin; H H Marti; S Roussel; D Divoux; A Nouvelot; E T MacKenzie; E Petit
Journal:  J Cereb Blood Flow Metab       Date:  1999-06       Impact factor: 6.200

8.  Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivative.

Authors:  Giovanni Grasso; Alessandra Sfacteria; Serhat Erbayraktar; Marcello Passalacqua; Francesco Meli; Necati Gokmen; Osman Yilmaz; Domenico La Torre; Michele Buemi; Domenico G Iacopino; Thomas Coleman; Anthony Cerami; Michael Brines; Francesco Tomasello
Journal:  J Neurosurg Spine       Date:  2006-04

9.  Recombinant human erythropoietin prevents the death of mice during cerebral malaria.

Authors:  Karine Kaiser; Anthony Texier; Josette Ferrandiz; Alain Buguet; Anne Meiller; Christine Latour; François Peyron; Raymond Cespuglio; Stéphane Picot
Journal:  J Infect Dis       Date:  2006-02-28       Impact factor: 5.226

10.  Inactivation of erythropoietin leads to defects in cardiac morphogenesis.

Authors:  H Wu; S H Lee; J Gao; X Liu; M L Iruela-Arispe
Journal:  Development       Date:  1999-08       Impact factor: 6.868

View more
  53 in total

1.  Erythropoietin-induced changes in brain gene expression reveal induction of synaptic plasticity genes in experimental stroke.

Authors:  Manuela Mengozzi; Ilaria Cervellini; Pia Villa; Zübeyde Erbayraktar; Necati Gökmen; Osman Yilmaz; Serhat Erbayraktar; Mathini Manohasandra; Paul Van Hummelen; Peter Vandenabeele; Yuti Chernajovsky; Alexander Annenkov; Pietro Ghezzi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

2.  Erythropoietin Stimulates Tumor Growth via EphB4.

Authors:  Sunila Pradeep; Jie Huang; Edna M Mora; Alpa M Nick; Min Soon Cho; Sherry Y Wu; Kyunghee Noh; Chad V Pecot; Rajesha Rupaimoole; Martin A Stein; Stephan Brock; Yunfei Wen; Chiyi Xiong; Kshipra Gharpure; Jean M Hansen; Archana S Nagaraja; Rebecca A Previs; Pablo Vivas-Mejia; Hee Dong Han; Wei Hu; Lingegowda S Mangala; Behrouz Zand; Loren J Stagg; John E Ladbury; Bulent Ozpolat; S Neslihan Alpay; Masato Nishimura; Rebecca L Stone; Koji Matsuo; Guillermo N Armaiz-Peña; Heather J Dalton; Christopher Danes; Blake Goodman; Cristian Rodriguez-Aguayo; Carola Kruger; Armin Schneider; Shyon Haghpeykar; Padmavathi Jaladurgam; Mien-Chie Hung; Robert L Coleman; Jinsong Liu; Chun Li; Diana Urbauer; Gabriel Lopez-Berestein; David B Jackson; Anil K Sood
Journal:  Cancer Cell       Date:  2015-10-17       Impact factor: 31.743

3.  Erythropoietin in the neurology ICU.

Authors:  Claudia Robertson; Saeed Sadrameli
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

4.  A surprising journey in translational medicine.

Authors:  Anthony Cerami
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

5.  Brain PET Poster Sessions PP01-M01 to PP02-N07.

Authors: 
Journal:  J Cereb Blood Flow Metab       Date:  2019-07       Impact factor: 6.200

6.  Carbamylated Erythropoietin Outperforms Erythropoietin in the Treatment of AKI-on-CKD and Other AKI Models.

Authors:  Florian E Tögel; Jon D Ahlstrom; Ying Yang; Zhuma Hu; Ping Zhang; Christof Westenfelder
Journal:  J Am Soc Nephrol       Date:  2016-03-16       Impact factor: 10.121

7.  Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.

Authors:  Lara Heij; Marieke Niesters; Maarten Swartjes; Elske Hoitsma; Marjolein Drent; Ann Dunne; Jan C Grutters; Oscar Vogels; Michael Brines; Anthony Cerami; Albert Dahan
Journal:  Mol Med       Date:  2012-11-15       Impact factor: 6.354

8.  Intranasal Erythropoietin Protects CA1 Hippocampal Cells, Modulated by Specific Time Pattern Molecular Changes After Ischemic Damage in Rats.

Authors:  R J Macias-Velez; L Fukushima-Díaz de León; C Beas-Zárate; M C Rivera-Cervantes
Journal:  J Mol Neurosci       Date:  2019-05-03       Impact factor: 3.444

9.  Erythropoietin Receptor Signaling Supports Retinal Function after Vascular Injury.

Authors:  Colin A Bretz; Aaron B Simmons; Eric Kunz; Aniket Ramshekar; Carson Kennedy; Ivan Cardenas; M Elizabeth Hartnett
Journal:  Am J Pathol       Date:  2020-02-21       Impact factor: 4.307

10.  ARA290 Improves Insulin Release and Glucose Tolerance in Type 2 Diabetic Goto-Kakizaki Rats.

Authors:  Carole Muller; Kamal Yassin; Luo-Sheng Li; Magnus Palmblad; Suad Efendic; Per-Olof Berggren; Anthony Cerami; Michael Brines; Claes-Göran Östenson
Journal:  Mol Med       Date:  2015-12-29       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.